ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders.